To more effectively treat neurodegenerative conditions, we first need diagnostic tools that lend a more complete picture of ...

Campaigners have called for a change in the way treatments for dementia are assessed in the wake of the decision on the drug ...

Campaigners have called for a change in the way treatments for dementia are assessed in the wake of the decision on the drug ...

AAN conference featured the latest research and developments in neurological disorders like Alzheimer's disease, epilepsy and ...

Full FDA approval of Eisai and Biogen’s Alzheimer’s disease therapy Leqembi may have unlocked the door to a broader rollout of the drug and potentially blockbuster sales, but commentators ...

The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China, and Japan gave a green light to ...

A good rule of thumb for protecting your brain health? If a neurologist wouldn’t do it, you probably shouldn’t either.

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System ...

BioArctic AB (publ) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System Atrophy (MSA) patients for treatment with the alpha-synuclein antibody ...

Research is constantly evolving in the world of cognitive health, including for neurological diseases for which there are currently no cures or guaranteed preventive methods. In regards to the most ...

Biogen (NasdaqGS:BIIB) appointed multiple co-lead underwriters for two fixed-income offerings totaling over $1 billion, showcasing its efforts to bolster financial offerings. This move, coupled with ...